Board of Directors
ImmunXperts’ Board of Directors is comprised of seasoned executives, each with many years of experience in managing Life Science companies
Philippe Janssens de Varebeke
— Chairman of the Board
Holds a PhD in Biochemistry & MBA – UCL. Started his career at the Catholic University of Louvain, than worked for several departments of Searle (now Pfizer) for more than 12 years. Since then he was a venture capitalist for several funds: EuroVentures Benelux, Sopartec and Vives. He is also active in the creation of start-up/spin-off companies. He is board member of several Life sciences companies. Since 8 years, he is Life Sciences Specialist for foreign investment projects of AWEX.
Author of many publications, patents and books including the reference book “Biotech Opportunities in Europe: Establishing and Operating a health Care Biotech Venture”.
Micheline Streel, 52, has a Bachelor of Business Administration (Université de Liège). She started her career in the banking sector. She had been working in the mid-market corporate for many years (Electronic banking, international payment, foreign-exchange and interest-rate risk management, cash management). In 2000, she worked as Account Manager and was in charge of the relationship between the bank and 70 SMEs (Business Developer, Risk Manager and Coordinator). In 2011, she joined Sambrinvest SA, a private equity and venture capital firm specializing in start up, spin off and spin out companies as well as a financing vehicle for different types of corporate investments. The scope of activity of Sambrinvest is geographically limited to the Charleroi and Thuin districts of Belgium.
Thibault started his career in the utilities sector, holding several financial and consultancy positions. In 2013 he joined MaSTherCell (cell therapy CDMO), where he helped grow the company from 10 to over 90 people in less than 3 years. In 2016 he joined ImmunXperts to continue putting his competences at the service of developing innovative therapies. Thibault holds a Master of Business Engineering from the Solvay Brussels School of Economics and Management.
Since 2012, ir. Stas is Chief Executive Officer of Trinean NV, a Belgium based developer of lab instrumentation. Prior to joining Trinean, Philippe headed the Applied Protein Services group of Lonza in Cambridge UK. As from 1999, Philippe was active with AlgoNomics, a Belgium based services provider specialized in Immunogenicity screening of protein therapeutics. As CEO, he sold the company to Lonza AG in 2009. He is founding president and acting secretary-general of the European Immunogenicity Platform EIP.
Sofie has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics). She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.